BRCA-associated pancreatic cancer: the evolving management.

Abstract

Pancreatic cancer is one of the deadliest cancers. While BRCA-associated pancreatic cancers are uncommon, the distinctive phenotype of this malignancy may offer unique therapeutic targets. At the 2013 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, a review of the characteristics and outcomes of one large case series (Abstract #278), however, did not reveal a benefit to first-line platinum chemotherapy in the treatment of advanced pancreatic cancer. In another study (Abstract #147), substantial responses were observed in both patients with BRCA2-associated pancreatic cancer treated with the poly-(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib). We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease.

DOI: 10.6092/1590-8577/1462

2 Figures and Tables

Cite this paper

@article{Leung2013BRCAassociatedPC, title={BRCA-associated pancreatic cancer: the evolving management.}, author={Keith King Wui Leung and Muhammad Wasif Saif}, journal={JOP : Journal of the pancreas}, year={2013}, volume={14 2}, pages={149-51} }